Re‐exploring immune‐related side effects of docetaxel in an observational study: Blood hypereosinophilia
Abstract Docetaxel is a major anticancer drug that can induce hypersensitivity reactions leading to deleterious treatment interruptions. Blood hypereosinophilia could be a biological sign, potentially lethal, of delayed visceral hypersensitivity reactions. We hypothesized this biological event is pr...
Main Authors: | Diaddin Hamdan, Christophe Leboeuf, Christine Le Foll, Guilhem Bousquet, Anne Janin |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-05-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.2062 |
Similar Items
-
Hypereosinophilia in respiratory diseases
by: A G Chuchalin
Published: (2003-03-01) -
DRESS Syndrome: An Unusual Side Effect
by: Kapil Bhalla, et al.
Published: (2019-02-01) -
Design of theranostic nanomedicine (II): synthesis and physicochemical properties of a biocompatible polyphosphazene–docetaxel conjugate
by: Jun YJ, et al.
Published: (2017-07-01) -
Testing, testing, testing: an insidious hypereosinophilia
by: Livia Robbiolo, et al.
Published: (2013-04-01) -
Hypereosinophilia and hepatitis C
by: Carlo Bussolino, et al.
Published: (2015-10-01)